feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Dow Jones awaits Fed decision

trending

ITR refund delays explained

trending

Court reverses Byju order

trending

Australia bans social media under 16

trending

India Post reengineering underway

trending

Union Bank tackles cyber risks

trending

Mexico tariff hits car exports

trending

Sabarimala gold heist case

trending

Ayushman cards issued to women

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New Blood Test Revolutionizes Breast Cancer Care

New Blood Test Revolutionizes Breast Cancer Care

11 Dec

•

Summary

  • A new blood test offers 90% accuracy in identifying breast cancer type changes.
  • This test eliminates the need for invasive biopsies for cancer type analysis.
  • The technology could potentially be applied to monitor and treat various cancers.
New Blood Test Revolutionizes Breast Cancer Care

A significant advancement in breast cancer care has emerged with the development of a new blood test capable of identifying cancer types without invasive biopsies. This innovative approach from the Institute of Cancer Research in London offers a faster, more accurate way to monitor breast cancer, as it can detect changes in cancer type that occur during treatment. These changes can render existing therapies ineffective, and previously required tissue biopsies to identify.

The trial demonstrated a 90% accuracy rate in detecting these critical shifts in cancer type, a crucial finding given that cancer can adapt over time. By analyzing circulating tumor DNA in the bloodstream, the test allows for real-time tracking of cancer evolution. This facilitates timely adjustments to treatment plans, ensuring patients receive therapies most likely to succeed and overcoming treatment resistance.

Experts believe the technology behind this Breast Circulating Methylation Assay (BCMA) could extend beyond breast cancer to various other cancer types. This opens new avenues for smarter, faster, and more personalized cancer care. While further clinical trials are needed, the early results are highly promising for improving patient survival and treatment efficacy.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The blood test identifies breast cancer types without a biopsy, allowing for quicker, personalized treatment adjustments when the cancer evolves.
The test showed 90% accuracy in a trial for identifying crucial shifts in breast cancer types during treatment.
Yes, scientists believe the technology behind the BCMA blood test has the potential to be applied to many other types of cancer.

Read more news on

Healthside-arrow

You may also like

Russia Develops AI Cancer Vaccine

9 hours ago • 2 reads

article image

Cancer Research Frozen: Grant Halts Life-Saving Work

9 Dec • 16 reads

article image

CHOP's CAR T Therapy Saves Young Lives

5 Dec • 26 reads

article image

Free Camp Detects Stomach Cancer in 6 Patients

1 Dec • 48 reads

article image

WHO Greenlights Pneubevax 14 for Global Use

21 Nov • 114 reads

article image